Watermark
Go to Asia edition

Alizyme

  • 22 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Citi 272,848.08 1048 8.12%
2 JPMorgan 265,005.45 1158 7.89%
3 Bank of America Merrill Lynch 247,670.24 827 7.37%
4 Barclays 202,639.20 746 6.03%
5 Goldman Sachs 181,377.67 593 5.40%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 BNP Paribas 34,133.57 140 6.41%
2 JPMorgan 32,550.71 62 6.11%
3 UniCredit 28,539.82 130 5.36%
4 SG Corporate & Investment Banking 28,297.17 109 5.32%
5 Deutsche Bank 26,254.12 90 4.93%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 11,195.88 46 9.08%
2 Goldman Sachs 10,193.27 47 8.26%
3 Citi 9,056.44 50 7.34%
4 Morgan Stanley 6,436.97 42 5.22%
5 UBS 6,098.17 23 4.94%